Minimizing the Regulatory Ripple Effect for Quality and Training in Drug Safety Organizations
Add bookmark
Minimizing the Regulatory Ripple Effect for Quality and Training in Drug Safety Organizations
Add bookmark
Even a slight change to a regulation can have a huge effect throughout an organization. Given the recent overhaul of the EMA drug safety requirements, the ‘ripple effect’ is more like a tidal wave. In this podcast, Amber Scorah of Pharma IQ, gets some best practices for minimizing ripples from two of Pfizer’s key leaders: Nancy Grey, Director, Quality Standards and Training, Worldwide Safety and Regulatory Operations, and Virginia Klunder, Director, Compliance Analytics, Qual...
Tags:
Nancy Grey
Virginia Klunder
quality
training
safety organizations
pharmacovigilance
drug safety
EMA drug safety requirements
compliance
